Quartalszahlen: Boom bei Abnehmspritzen hält an – Eli Lilly hebt Prognose an
Die Nachfrage nach Abnehm- und Diabetesmitteln beschert Eli Lilly kräftiges Wachstum. Der US-Pharmakonzern hebt seine Umsatzprognose für 2026 an – und übertrifft die Erwartungen deutlich.
Frankfurt - Eli Lilly, the U.S. pharmaceutical company, has raised its revenue forecast for 2026 due to sustained high demand for its weight loss and diabetes treatment medications. The company now projects sales to range between $85 and $87 billion for the year, up from the previously anticipated $82 to $85 billion. This robust growth is expected to reassure investors that demand for Eli Lilly's weight loss products remains resilient despite pricing pressures and increasing competition in the market.
The company's shares surged by five percent in pre-market trading. In the second quarter, revenue climbed by 48 percent to $23 billion, primarily driven by blockbuster hits Mounjaro and Zepbound for diabetes and weight management, respectively. Net income increased by a quarter to just under $7.1 billion, and adjusted earnings per share reached $8.38, significantly surpassing analysts' expectations of an average $6.01.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
